Qiming Venture Partners Leads Over 100 Million Yuan Series A Financing in Tianwu Tech, an AI-Powered Protein Design Pioneer

Nov 15, 2024 10:03 CST Updated 10:03

Matwings Technology

AI Protein Design Service Provider

On November 15, Matwings Technology, an AI protein design company with international leadership, announced the completion of its Series A financing round exceeding 100 million yuan.This round of financing was led by Qiming Venture Partners, with participation from Yonghua Investment, Jingtao Capital, and existing shareholder Panacea Venture, among other institutions.The funds raised will be mainly used for the development of self-research projects and the continuous iteration and upgrading of AccelProtein™, a general artificial intelligence for protein design (originating from the Pro series artificial intelligence developed by the Hong Liang team at Shanghai Jiao Tong University), to ensure that Matwings Technology maintains a leading position in global technological innovation and market competitiveness.

AccelProtein™：

Predict Protein Function, Revolutionize Protein Design

Proteins are omnipresent in our daily life and production, serving as the foundation for maintaining life activities and driving technological innovation. High-performance protein products are the source of progress in many industries such as biomedicine, green energy, food health, and green chemical engineering. However, traditional methods often face challenges such as high costs, complex processes, and low success rates when obtaining high-performance proteins.

The innovation of Matwings Technology lies in its self-developed general artificial intelligence for protein design, AccelProtein™, which is capable ofDirectly predicting protein functions breaks through the limitation of structure prediction methods represented by AlphaFold, which "can only predict structures but cannot design functions," providing a completely new technical means for obtaining proteins with excellent functions, and standing out uniquely in the industry.

Focusing on Biopharmaceuticals and Synthetic Biology

Empowering the Upgrade of Biomanufacturing Industry

Currently, Matwings Technology's general artificial intelligence for protein design, AccelProtein™, has achieved directed mining and evolution of proteins in numerous scenarios within biomedicine and synthetic biology, including significant improvements in indicators such as protein thermal stability, activity, affinity, extreme pH tolerance, immunogenicity, and yield.

In the CMC stage of biopharmaceuticals, AccelProtein™ can enhance the activity, specificity, thermal stability, and pH stability of key tool enzymes and tool proteins; in the early large-molecule screening stage, it can increase the affinity and functional activity of fusion proteins, antibodies, and cytokines for their targets; in the candidate molecule optimization stage, it provides druggability index modification and property optimization (including improving molecular stability, reducing viscosity, etc.), precisely addressing critical pain points pharmaceutical companies face during R&D and production.

In the field of synthetic biology, Matwings Technology relies on AccelProtein™ for enzyme modification, enzyme mining, and enzymatic process development to address the challenges of precise synthesis of high-value molecules that are difficult to solve through chemical synthesis or natural extraction. It provides efficient and green AI-driven enzymatic solutions for fields such as pharmaceutical intermediates, fragrances, health product ingredients, and cosmetic raw materials.

After more than three years of development, Matwings Technology has successfully delivered over thirty protein design projects, serving leading companies in various industries such as innovative drugs, in vitro diagnostics, pharmaceutical intermediates, nutritional health, food and beverages, cleaning and textiles, and bio-agriculture. In the future, Matwings Technology will further deepen the application of its AI protein design technology, accelerate innovation in the biopharmaceutical and synthetic biology fields, and promote bio-manufacturing towards a more efficient and environmentally friendly direction.

Jointly Build a Biomedical Innovation Ecosystem!

How to Join BiG Membership?